# American Vanguard Corp: Form 10-Q for the period ended Sep 30, 2018

- Company: [American Vanguard Corp](/companies/avd.md) (CIK 5981)
- Form: 10-Q
- Filed: 2018-11-06
- Accepted by EDGAR: Nov 6, 2018, 17:05 ET
- Period: 2018-09-30
- Accession: 0001564590-18-027505
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/5981/000156459018027505/avd-10q_20180930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/5981/000156459018027505/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2018-07-01 to 2018-09-30 | $111.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2018-01-01 to 2018-09-30 | $322.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2018-07-01 to 2018-09-30 | $66.5m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2018-01-01 to 2018-09-30 | $193.3m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2018-07-01 to 2018-09-30 | $45.3m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2018-01-01 to 2018-09-30 | $129.6m | us-gaap:GrossProfit |
| Operating income | 3 months, 2018-07-01 to 2018-09-30 | $11.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2018-01-01 to 2018-09-30 | $27.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2018-07-01 to 2018-09-30 | $1.1m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2018-01-01 to 2018-09-30 | $3.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2018-07-01 to 2018-09-30 | $3.5m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2018-01-01 to 2018-09-30 | $7.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2018-07-01 to 2018-09-30 | $6.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2018-01-01 to 2018-09-30 | $16.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-07-01 to 2018-09-30 | $0.22 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2018-01-01 to 2018-09-30 | $0.56 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2018-07-01 to 2018-09-30 | $0.22 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2018-01-01 to 2018-09-30 | $0.57 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2018-07-01 to 2018-09-30 | 30,209,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2018-01-01 to 2018-09-30 | 30,146,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2018-01-01 to 2018-09-30 | −$15.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Dividends paid | 9 months, 2018-01-01 to 2018-09-30 | $1.6m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2018-09-30 | $9.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-09-30 | $320.8m | us-gaap:AssetsCurrent |
| Total assets | at 2018-09-30 | $589.9m | us-gaap:Assets |
| Current liabilities | at 2018-09-30 | $137.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2018-09-30 | $261.3m | us-gaap:Liabilities |
| Long-term debt | at 2018-09-30 | $97.3m | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | at 2018-09-30 | $0 | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2018-09-30 | $328.5m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 39,492 characters.

### FORWARD-LOOKING STATEMENTS/RISK FACTORS:

The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company’s operations, future results and prospects. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and other factors. In connection with the Private Securities Litigation Reform Act of 1995, the Company provides the following cautionary statements identifying important factors which, among other things, could cause the actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire Report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources; general business regulations, including taxes and other risks as detailed from time-to-time in the Company’s reports filed with the U.S. Securities and Exchange Commission (the “SEC”). It is not possible to foresee or identify all such factors. For more detailed information, refer to Item 1A., Risk factors and Item 7A., Quantitative and Qualitative Disclosures about Market Risk, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

### MANAGEMENT OVERVIEW

The Company’s operating results for the three months ended September 30, 2018, were improved over the same period of 2017, with net sales up 24% ($111,780 as compared to $89,975), net income attributable to American Vanguard up 60% ($6,525 v. $4,089), gross profit up approximately 19% ($45,300 v. $38,032), gross margin down to 41% from 42% of net sales and operating expenses up 7% ($33,635 v. $31,570), but down as a percentage of sales to 30% in 2018, as compared to 35% for the same period of the prior year.

Top line sales growth for the third quarter of 2018 was primarily driven by sales of both AgriCenter (with multiple products sold into the Central America region) and OHP (with an extensive range of non-crop horticultural products), which were acquired in the final quarter of 2017 and therefore not included in the prior year sales for the third quarter of 2017. Performance of pre-existing products was essentially flat with reductions in Naled® (high demand in the comparative period of 2017 related to hurricanes Harvey and Irma), lower tolling and lower international demand for Nemacur® (primarily related to timing). These reductions were substantially offset by improvements in net sales of Folex® (on cotton), Dacthal and Mocap. Gross profit decreased from 42% of net sales to 41% of net sales quarter-over-quarter, due largely to the inclusion of the Central American distribution business which drives high sales at lower margins and was also affected by a beneficial adjustment of management’s estimate for inventory reserves. This downward pressure on gross profit was offset by a continued strong manufacturing performance during the three month period, during which our factory costs were fully absorbed.

While rising on an absolute basis by 7%, operating expenses declined as a percentage of sales from 35% in the third quarter of 2017 to 30% in the third quarter of 2018. The improved performance (compared to sales) reflects economies of scale achieved overall notwithstanding increases necessary to manage the newly acquired businesses and products. Those expanded costs were partially offset by reductions in deferred consideration associated with the businesses acquired in the final quarter of 2017. Net income was impacted by finalizing the transition tax related to the implementation of the Tax Cuts and Jobs Act. We completed our review of our historical international tax returns and concluded that the Company has additional liabilities in the amount of $1,089, which were recorded in the condensed consolidated financial statements for the three months ended September 30, 2018. Including this additional one-time tax expense, our net income increased by $2,436 or 60%, as compared to the three months ended September 30, 2017.

The Company’s operating results for the nine months ended September 30, 2018, were also improved over the same period of 2017, with net sales up 35% ($322,934 compared to $238,553), net income (including the same one-time transition tax expense) attributable to American Vanguard up 42% ($16,779 v. $11,845), gross profit up approximately 27% ($129,648 v. $102,451), gross margin down to 40% from 43% of net sales and operating expenses up 21% ($102,011 v. $84,175), but down as a percentage of sales to 32% in 2018, as compared to 35% for the same period of the prior nine months.

For the nine month period ended September 30, the underlying story is similar. The improvement in net sales for the first nine months of 2018 was driven primarily by sales of recently acquired product lines and businesses. Performance of pre-existing products was basically stable and included increased sales of Folex ® (a cotton defoliant), soil fumigants (Metam and k-pam®H.L.) Impact, Dacthal ® (high value vegetable crops) and Mocap, offset by lower sales of our vector control product for mosquitos, which had unusually high sales in 2017 and by a decline in Bidrin as a result of lower pest pressure on cotton. Gross margin decreased from 43% in the nine months of 2017 to 40% for the same period in 2018 due to increased sale of lower margin products, including the products and distribution businesses acquired in 2017. Factory performance improved in comparison to the same nine-month period of 2017; net factory costs were less than a half percent of sales in 2018, as compared to 3% of sales in 2017. During the first nine months of the year, operating expenses rose on an absolute basis, but dropped as a percentage of net sales from 35% to 32% driven by economies of scale of the Company’s expanded business. Notwithstanding the one-time adjustment for the transition tax discussed earlier, net income for the nine months ended September 30, 2018 rose by $4,934 or 42% as compared to the nine months ended September 30, 2017.

When considering the condensed consolidated balance sheet, as of September 30, 2018, net debt has increased by $19,827, at September 30, 2018, as compared to December 31, 2017. This increase was to fund working capital for our expanded businesses. Debt, net of deferred loan fees, at September 30, 2018 and at December 31, 2017 was $97,313 and $77,486, respectively. As of September 30, 2018, the Company had the capacity to borrow $105,111 as compared to $124,724 as of September 30, 2017.

### RESULTS OF OPERATIONS

### Quarter Ended September 30:

| Net sales: | 2018 | 2017 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Insecticides | $25,475 | $24,866 | $609 | 2% |
| Herbicides/soil fumigants/fungicides | 34,577 | 32,717 | 1,860 | 6% |
| Other, including plant growth regulators | 35,302 | 17,191 | 18,111 | 105% |
| Total crop | 95,354 | 74,774 | 20,580 | 28% |
| Non-crop | 16,426 | 15,201 | 1,225 | 8% |
|  | $111,780 | $89,975 | $21,805 | 24% |
| Cost of sales: |  |  |  |  |
| Insecticides | $16,543 | $16,141 | $402 | 2% |
| Herbicides/soil fumigants/fungicides | 19,421 | 19,551 | (130) | -1% |
| Other, including plant growth regulators | 22,081 | 10,230 | 11,851 | 116% |
| Total crop | 58,045 | 45,922 | 12,123 | 26% |
| Non-crop | 8,435 | 6,021 | 2,414 | 40% |
|  | $66,480 | $51,943 | $14,537 | 28% |
| Gross profit: |  |  |  |  |
| Insecticides | $8,932 | $8,725 | $207 | 2% |
| Herbicides/soil fumigants/fungicides | 15,156 | 13,166 | 1,990 | 15% |
| Other, including plant growth regulators | 13,221 | 6,961 | 6,260 | 90% |
| Gross profit crop | 37,309 | 28,852 | 8,457 | 29% |
| Gross profit non-crop | 7,991 | 9,180 | (1,189) | -13% |
|  | $45,300 | $38,032 | $7,268 | 19% |
| Gross margin crop | 39% | 39% |  |  |
| Gross margin non-crop | 49% | 60% |  |  |
| Total gross margin | 41% | 42% |  |  |

| Net sales: | 2018 | 2017 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| US | $71,711 | $65,842 | $5,869 | 9% |
| International | 40,069 | 24,133 | 15,936 | 66% |
|  | $111,780 | $89,975 | $21,805 | 24% |

For the three months ended September 30, 2018, within our crop business, net sales of our insecticides group were up approximately 2.5% to end at $25,475, as compared to $24,866 during the third quarter of 2017. Within this category, net sales of our granular insecticides were down approximately 5% due to reduced demand for Nemacur and a slight reduction in Counter (for nematode control), offset by improved sales of Thimet® (domestic sugarcane) and Mocap (both domestic and international demand). Net sales of our non-granular crop insecticides were up, as this category benefitted from increased sales of our Bidrin foliar insecticide for cotton.

Within the group of herbicides/fungicides/fumigants used in crop applications, net sales for the third quarter of 2018 increased by approximately 5.7% to $34,577 from $32,717 in the comparable period of 2017. Net sales of our herbicide products increased approximately 19%, with greater sales of Dacthal and newly introduced ametryn products in Mexico, more than offsetting reduced sales of paraquat in the domestic market and bromacil internationally. Further, sales of our corn herbicide, Impact, were higher in the quarter due to the fact that we had taken a charge for price reduction of channel inventory of Impact in the third quarter of 2017 but took no such charge during the comparable quarter in 2018. Our soil fumigants business declined slightly from the prior year’s third quarter due to wet weather, which inhibited application in the Northwest potato market. In fungicides, we had steady sales of our PCNB® product and posted additional sales of the newly acquired chlorothalonil fungicide, Equus®.

Within the group of other products (which includes our AgriCenter distribution business in Central America, plant growth regulators, molluscicides and tolling activity), net sales were up 105%, as compared to the third quarter of 2017. AgriCenter distributes crop protection products and crop nutrient inputs to the growers of numerous tropical crops such as bananas, pineapples, and citrus fruits primarily in Costa Rica, Nicaragua, Honduras, Panama, and the Dominican Republic and reported approximately $18,000 in the net sales for three months ended September 30, 2018. Since the AgriCenter acquisition was concluded in the final quarter of 2017, no sales are in the comparable prior year period. With regard to our pre-acquisition products, our cotton harvest defoliant Folex®, posted significant quarterly sales gains due to increased cotton acres in two of our key market segments (the MidSouth and Southeast). Offsetting these strong factors we had slightly lower sales of our Metaldehyde granules, and our SmartBlock® potato sprout inhibitor, as well as reduced revenues from toll manufacturing.

Our non-crop sales ended the third quarter of 2018 at $16,426 up 8.1%, as compared to $15,201 for the same period of the prior year. We experienced a year-over-year decline in our aerial-applied mosquito adulticide Dibrom® as compared to the extraordinary demand for insect control following hurricanes Harvey and Irma in 2017. This decline was more than offset by the incremental sales of our recently acquired OHP horticulture business and a strong uptick in our Pest Strip business.

Our international sales increased 66% ending at $40,069, as compared to $24,133 for the third quarter of the prior year. This improvement was driven by AgriCenter which was acquired in the fourth quarter of 2017 and is not included in the prior year performance as a consequence. During the three months ended September 30, 2018, the Agricenter group recorded approximately $18,000. In addition, we recorded strong sales of our Mocap brand, offsetting slightly lower sales of our Hyvar®/ Krovar® herbicide brands and our Nemacur insecticide.

Our cost of sales for the third quarter of 2018 was $66,480 or 59% of sales. This compared to $51,943 or 58% of sales for the same period of 2017. The increase in cost of sales as a percentage of net sales in 2018 is driven by the impact of the mix change including the effect of acquired products and distribution businesses, which drive high sales but at comparatively lower margins than our pre-existing business. This effect was partly offset by our factory activity which improved to the extent that we fully recovered our factory costs for the quarter.

Gross profit for the third quarter of 2018 improved by $7,268, or 19%, to end at $45,300, as compared to $38,032 for the third quarter of 2017. Gross margin percentage ended at 41% in the three months ended September 30, 2018, as compared to 42% in the same period of the prior year. As previously noted, the change in performance is largely driven by the new products and businesses acquired in 2017 and partially offset by our improved factory performance.

As discussed below in detail by department, operating expenses increased by $2,065 (or 7%) to $33,635 for the three months ended September 30, 2018, as compared to the same period in 2017. The differences in operating expenses by department are as follows:

|  | 2018 | 2017 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Selling | $9,637 | $6,671 | $2,966 | 44% |
| General and administrative | 8,686 | 9,227 | (541) | -6% |
| Research, product development and regulatory | 5,895 | 7,324 | (1,429) | -20% |
| Freight, delivery and warehousing | 9,417 | 8,348 | 1,069 | 13% |
|  | $33,635 | $31,570 | $2,065 | 7% |

- Selling expenses increased by $2,966 to end at $9,637 for the three months ended September 30, 2018, as compared to the same period of 2017. The main driver resulted from increased sales activities associated with the newly acquired distribution businesses.
- General and administrative expenses decreased by $541 to end at $8,686 for the three months ended September 30, 2018, as compared to the same period of 2017. The decrease was driven by the quarterly re-assessment of fair value associated with deferred consideration for newly acquired businesses in the amount of $3,969. This decrease was offset by an increase in incentive compensation costs in the amount of $837, the inclusion of activities associated with products and

businesses acquired in 2017 including amortization in the amount of $462, reserves of doubtful debts in our AgriCenter business in the amount of $335 and higher legal costs of approximately $800, mainly associated with the Company’s prosecution of its takings case against USEPA.

- Research, product development costs and regulatory expenses decreased by $1,429 to end at $5,895 for the three months ended September 30, 2018, as compared to the same period of 2017. The decrease is related to the level of regulatory activity defending our portfolio of products.
- Freight, delivery and warehousing costs for the three months ended September 30, 2018 were $9,417 or 8.4% of sales as compared to $8,348 or 9.4% of sales for the same period in 2017. This improvement was primarily driven by the mix of sales, including lower sales of our high volume bulk fumigant products, in comparison to the same period of the prior year.

Interest costs net of capitalized interest, were $1,116 in the three months ended September 30, 2018, as compared to $375 in the same period of 2017. Interest costs are summarized in the following table:

### Average Indebtedness and Interest expense

|  | Three months ended September 30, 2018 Average Debt | Interest Expense | Interest Rate | Three months ended September 30, 2017 Average Debt | Interest Expense | Interest Rate |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revolving line of credit (average) | $80,001 | $822 | 4.1% | $44,897 | $320 | 2.9% |
| Amortization of deferred loan fees | — | 60 | — | — | 57 | — |
| Amortization of other deferred liabilities | — | 107 | — | — | 7 | — |
| Other interest (income) expense | — | 146 | — | — | 7 | — |
| Subtotal | 80,001 | 1,135 | 5.7% | 44,897 | 391 | 3.5% |
| Capitalized interest | — | (19) | — | — | (16) | — |
| Total | $80,001 | $1,116 | 5.6% | $44,897 | $375 | 3.3% |

The Company’s average overall debt for the three months ended September 30, 2018 was $80,001, as compared to $44,897 for the three months ended September 30, 2017. This increase arose primarily from borrowing activity required to fund acquisitions during the fourth quarter of 2017. During the third quarter of 2018, we continued to focus on managing our working capital and controlling our usage of revolving debt. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 4.1% for the three months ended September 30, 2018, as compared to 2.9% in 2017.

Income tax expense increased by $1,572 to end at an expense of $3,526 for the three months ended September 30, 2018, as compared to $1,954 for the comparable period in 2017. The effective tax rate for the quarter was 33.4%, as compared to 32.1% in the same period of the prior year. Our effective tax rate increased due to the inclusion of a one-time adjustment related to the implementation of the 2017 transition tax in the amount of $1,089. Excluding this one-time expense, the underlying effective tax rate for the quarter was 23.1%. Furthermore, the effective tax rate for all interim periods is based on the projected income for the full year and is subject to ongoing review and adjustment by management.

During the three months ended September 30, 2018 the Company recognized a loss of $352 on our investment in TyraTech based upon its forecasted financial performance for the full year. This compared to a loss of $29 recognized in the comparable period of 2017. The Company’s investment in TyraTech is included in other assets on the condensed consolidated balance sheets.

During the three months ended September 30, 2018, the Company recognized a loss of $181 through its Hong Kong Joint Venture on our investment in Profeng. This compared to a loss of $86 in the comparable period of 2017. The Company’s investment in the Hong Kong Joint Venture is included in other assets on the condensed consolidated balance sheets.

Non-controlling interest amounted to income of $35 in the three months ended September 30, 2018, as compared to $71 in the same period of the prior year. Non-controlling interest represents the share of net income that is attributable to the minority stockholder of our majority owned subsidiary, Envance.

Our net income for the three months ended September 30, 2018 was $6,525 or $0.22 per basic and diluted share, as compared to $4,089 or $0.14 per basic and diluted share in the same period of 2017.

### Nine Months Ended September 30:

| Net sales: | 2018 | 2017 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Insecticides | $99,433 | $102,249 | $(2,816) | -3% |
| Herbicides/soil fumigants/fungicides | 98,163 | 68,783 | 29,380 | 43% |
| Other, including plant growth regulators | 83,519 | 30,680 | 52,839 | 172% |
| Total crop | 281,115 | 201,712 | 79,403 | 39% |
| Non-crop | 41,819 | 36,841 | 4,978 | 14% |
| Total net sales | $322,934 | $238,553 | $84,381 | 35% |
| Cost of sales: |  |  |  |  |
| Insecticides | $60,261 | $64,495 | $(4,234) | -7% |
| Herbicides/soil fumigants/fungicides | 55,502 | 38,221 | 17,281 | 45% |
| Other, including plant growth regulators | 56,127 | 17,418 | 38,709 | 222% |
| Total crop | 171,890 | 120,134 | 51,756 | 43% |
| Non-crop | 21,396 | 15,968 | 5,428 | 34% |
| Total cost of sales | $193,286 | $136,102 | $57,184 | 42% |
| Gross profit: |  |  |  |  |
| Insecticides | $39,172 | $37,754 | $1,418 | 4% |
| Herbicides/soil fumigants/fungicides | 42,661 | 30,562 | 12,099 | 40% |
| Other, including plant growth regulators | 27,392 | 13,262 | 14,130 | 107% |
| Gross profit crop | 109,225 | 81,578 | 27,647 | 34% |
| Gross profit non-crop | 20,423 | 20,873 | (450) | -2% |
| Total gross profit | $129,648 | $102,451 | $27,197 | 27% |
| Gross margin crop | 39% | 40% |  |  |
| Gross margin non-crop | 49% | 57% |  |  |
| Total gross margin | 40% | 43% |  |  |

| Net sales: | 2018 | 2017 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| US | $205,889 | $173,877 | $32,012 | 18% |
| International | 117,045 | 64,676 | 52,369 | 81% |
| Total net sales | $322,934 | $238,553 | $84,381 | 35% |

Sales for the nine months ended September 30, 2018 improved by 35.4% to end at $322,934, as compared to $238,553, this time last year. This year-over-year improvement was driven by incremental sales attributable to the acquisition of three new products and two new business units in 2017. During the period our pre-existing product lines included a significant reduction in Naled sales which, in 2017, were unusually high in response to hurricanes Harvey and Irma. The balance of our pre-existing product portfolio showed a stable overall performance.

Across our crop business, net sales of our insecticides group were down approximately 2.8% to end at $99,433, as compared to $102,249 during the nine months ended September 30, 2017. Within this category, net sales of our non-granular insecticides benefited from the 2017 product acquisition of Abba Ultra, while net sales of our granular soil insecticides, including Aztec® and SmartChoice (corn insectides) and Thimet (used primarily in peanuts and sugarcane) were down slightly. Our International insecticide business was relatively flat, with stronger sales of Mocap offset by softer sales of our Nemacur brand.

Within the group of herbicides/fungicides/fumigants used in crop applications, net sales for the nine months ended September 30, 2018 increased by approximately 43% to $98,163 from $68,783 in the comparable period of 2017. During the period, we saw stronger sales of our post-emergent corn herbicide Impact® and the newly introduced version Impact-Z in the Midwest region. We also benefitted from the continued strength of our Dacthal herbicide and the incremental sales of paraquat herbicide Parazone® (acquired in 2017), both providing solutions to the growing need for weed resistance management. We experienced steady sales of our Scepter® soybean herbicide sold in the U.S. market, increased sales of our Hyvar® and Krovar® herbicides, which are sold in international markets, and the incremental gain of newly introduced Bravo and Gesapax herbicide products into the Mexican market. Our soil fumigants business grew by 8% from the prior year, despite wet weather in several regions of the United States, which inhibited some applications of these liquid products. In the fungicide category, we had incremental sales of the newly acquired chlorothalonil fungicide, Equus and steady sales from our traditional product PCNB.

Within the group of other products (which includes our Central America distribution business, AgriCenter, plant growth regulators, molluscicides and tolling activity), net sales were up about 172%, as compared to the first nine months of 2017. The primary driver for the increased sales was the inclusion of the AgriCenter which recorded sales of approximately $52,000 in the nine months period ended September 30, 2018. (There were no AgriCenter sales in the nine months to September 30, 2018.) In addition, we recorded significantly higher sales of our Folex® cotton defoliant, due to increased harvested cotton acres in 2018, and stronger sales of our growth regulator product Citrus Fix. Offsetting these upside performances, we experienced softer sales of our growth regulator NAA, our Metaldehyde granules, and 2018 manufacturing tolling revenues were lower than the prior year’s nine-month period.

Our year-to-date non-crop sales ended up about 13.5% at $41,819, as compared to $36,841 for the same period of the prior year. This increase arose largely from new horticulture product sales through OHP. This increase was somewhat offset by reduced sales of Dibrom mosquito adulticide, which, while strong, were below the record sales that we experienced during the first nine months of 2017, following hurricanes Harvey (Texas) and Irma (Florida & Georgia). Additionally, we had slightly lower sales of our pharmaceutical products and a received a lower year-over-year royalty payment on our Envance consumer pest control products.

Our international sales were up 81% to end at $117,045, as compared to $64,676 for the first nine month of the prior year. The major driver within this category is the inclusion of sales from the Central American distribution business of AgriCenter. In addition, we posted increased sales of our Mocap insecticide and our Hyvar® and Krovar® herbicide products, which were somewhat offset by reduced sales of our Nemacur insecticide.

Our cost of sales for the first nine months of 2018 ended at $193,286 or 60% of net sales. This compares to $136,102 or 57% of net sales in the same period of 2017. The increase in cost of sales as a percentage of net sales in 2018 is driven by the impact of the mix change including the effect of acquired products and distribution businesses purchased during 2017. Those businesses drive high sales but at comparatively lower margins. This effect was somewhat offset by our factory activity which improved in 2018 to the extent that we have almost fully recovered our factory costs during the first nine months. Net factory costs for 2018 year-to-date amount to less than one half percent of sales, whereas net factory cost in the same period of 2017 amounted to 3% of sales.

Gross profit for the nine months ended September 30, 2018 improved by $27,197, or 27%, to end at $129,648, as compared to $102,451 for the first nine months of 2017. Gross margin percentage ended at 40% in the first nine months of 2018, as compared to 43% in the same period of the prior year. As previously noted, the change in performance is largely driven by the new businesses and products acquired in 2017.

Operating expenses increased by $17,836 to $102,011 for the nine months ended September 30, 2018, as compared to the same period in 2017. The changes in operating expenses by department are as follows:

|  | 2018 | 2017 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Selling | $29,617 | $19,833 | $9,784 | 49% |
| General and administrative | 29,410 | 27,137 | 2,273 | 8% |
| Research, product development and regulatory | 19,458 | 19,013 | 445 | 2% |
| Freight, delivery and warehousing | 23,526 | 18,192 | 5,334 | 29% |
|  | $102,011 | $84,175 | $17,836 | 21% |

- Selling expenses increased by $9,784 to end at $29,617 for the nine months ended September 30, 2018, as compared to the same period of 2017. The main drivers were an increase in activities from the newly acquired businesses during the end of 2017 and increased advertising and marketing activities in both our domestic and international regions.
- General and administrative expenses increased by $2,273 to end at $29,410 for the nine months ended September 30, 2018, as compared to the same period of 2017. The main drivers for the increases are primarily the inclusion of administrative activities of those newly acquired products and businesses, including increased amortization expense of $1,405 and increased reserve for doubtful accounts receivables related to AgriCenter in the mount of $499, increased incentive compensation costs in the amount of $1,316, and increased legal costs by $600 mainly associated with the Company’s prosecution of its takings case against the USEPA. These increases were partially offset by our re-assessment of the fair value of liabilities in the amount of $5,437 associated with the deferred consideration for the businesses acquired in 2017.
- Research, product development costs and regulatory expenses increased by $445 to end at $19,458 for the nine months ended September 30, 2018, as compared to the same period of 2017. The main driver for the increase was related to the activities of the newly acquired businesses, which was partially offset by the decrease in business development activities.
- Freight, delivery and warehousing costs for the nine months ended September 30, 2018 were $23,526 or 7.3% of sales as compared to $18,192 or 7.6% of sales for the same period in 2017. This improvement was primarily driven by the mix of sales and customer destinations in 2018 year to date, as compared to the same period of the prior year.

Interest costs net of capitalized interest were $2,961 in the first nine months of 2018, as compared to $1,073 in the same period of 2017. Interest costs are summarized in the following table:

### Average Indebtedness and Interest expense

|  | Nine months ended September 30, 2018 Average Debt | Interest Expense | Interest Rate | Nine months ended September 30, 2017 Average Debt | Interest Expense | Interest Rate |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revolving line of credit (average) | $92,971 | $2,399 | 3.4% | $44,706 | $870 | 2.6% |
| Amortization of deferred loan fees | — | 177 | — | — | 182 | — |
| Amortization of other deferred liabilities | — | 261 | — | — | 23 | — |
| Other interest (income) expense | — | 178 | — | — | 63 | — |
| Subtotal | 92,971 | 3,015 | 4.3% | 44,706 | 1,138 | 3.4% |
| Capitalized interest | — | (54) | — | — | (65) | — |
| Total | $92,971 | $2,961 | 4.2% | $44,706 | $1,073 | 3.2% |

The Company’s average overall debt for the nine months ended September 30, 2018 was $92,971, as compared to $44,706 for the nine months ended September 30, 2017. The difference in average debt levels between the two periods relates to the businesses acquired during the final quarter of 2017. During the nine months ended September 30, 2018, we continued to focus on managing our working capital and controlling our usage of revolving debt. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 3.4% for the nine months ended September 30, 2018, as compared to 2.6% in 2017.

Income tax expense increased by $1,951 to end at an expense of $6,966 for the nine months ended September 30, 2018, as compared to $5,015 for the comparable period in 2017. The effective tax rate for the nine months ended September 30, 2018 was 28.2%, as compared to 29.2% in the same period of the prior year. The decrease in our effective tax rate was due to the implementation of the Tax Cuts and Jobs Act and was partly offset in the period by an additional one-time charge of $1,089 related to finalizing transition tax on the Company’s historical overseas earning. If this one-time charge had not been included our effective rate would have been 23.8%. The effective tax rate for all interim periods is based on the projected income for the full year and is subject to ongoing review and adjustment by management.

During the nine months ended September 30, 2018 we recognized a loss of $795 on our investment in TyraTech. This compared to a loss of $140 recognized in the comparable period of 2017. This reflected their forecast financial performance for 2018 and a true up of their 2017 performance, which improved in comparison to 2016. The Company’s investment in TyraTech is included in other assets on the condensed consolidated balance sheets.

During the nine months ended September 30, 2018, the Company recognized a loss of $256 through our Hong Kong Joint Venture on its investment in Profeng. This compared to a loss of $86 in the comparable period of 2017. The Company’s investment in the Hong Kong Joint Venture is included in other assets on the condensed consolidated balance sheets.

Non-controlling interest amounted to an income of $120 in the nine months ended September 30, 2018, as compared to a loss of $117 in the same period of the prior year. Non-controlling interest represents the share of net income that is attributable to the minority stockholder of our majority owned subsidiary, Envance.

Net income for the nine months ended September 30, 2018 was $16,779 or $0.57 per basic and $0.56 per diluted share, as compared to $11,845 or $0.41 per basic and $0.40 per diluted share in the same period of 2017.

### LIQUIDITY AND CAPITAL RESOURCES

The Company used cash of $15,090 in operating activities during the nine months ended September 30, 2018, as compared to generating $18,244 by operating activities during the nine months ended September 30, 2017. Included in the $15,090 are net income of $16,659, plus non-cash depreciation, amortization of intangibles and other assets and discounted future liabilities, in the amount of $18,177, stock based compensation of $4,235, changes in deferred income taxes of $34 and losses from equity method investments of $1,051. The total provided net cash inflows of $40,088, as compared to $32,152 for the same period of 2017.

As of September 30, 2018, the Company increased working capital by $54,200, as compared to working capital at December 31, 2017. Inventories increased by $39,305, driven by our expanded business as we work through the related annual business cycles. Deferred revenue decreased by $13,965, driven by customer decisions regarding product demand, payment timing and our cash incentive programs. Our accounts payable balances increased by $5,711 driven by increased manufacturing activity and the impact of new business cycles associated with our distribution businesses. Accounts receivables increased by $24,382 driven primarily by AgriCenter sales as the agricultural market in Central America reaches high season plus strong sales growth and the business is not in the comparable prior period because it was acquired in the final quarter of 2017. Prepaid expenses increased by $959 and income tax payable increased by $2,069. Accrued programs increased by $22,882. Finally, other payables and accrued expenses decreased by $7,229.

With regard to our program accrual, the change primarily reflects our mix of sales and customers in the first nine months of 2018, as compared to the prior year. The Company accrues programs in line with the growing season upon which specific products are targeted. Most of our programs relate to domestic products. Typically, domestic crops have a growing season that ends on September 30th of each year. During the first nine months of 2018, the Company made accruals for programs in the amount of $38,027 and made payments in the amount of $15,145. During the first nine months of 2017, the Company made accruals in the amount of $37,738 and made payments in the amount of $15,018.

Cash used for investing activities was $6,788 for the nine months ended September 30, 2018, as compared to $32,187 for the nine months ended September 30, 2017. The Company spent $5,154 on fixed assets primarily focused on continuing to invest in manufacturing infrastructure, $344 reduction related to additional purchase accounting adjustments related to the AgriCenter business acquired in the fourth quarter of 2017 and $1,978 for the acquisition of the bromacil product line for sales in the USA on June 20, 2018.

The Company has a revolving line of credit that is shown as long-term debt in the condensed consolidated balance sheets at September 30, 2018 and December 31, 2017. The debt is summarized in the following table:

| Long-term indebtedness ($000's) | September 30, 2018 | December 31, 2017 |
| --- | ---: | ---: |
| Revolving line of credit | $98,100 | $78,425 |
| Deferred loan fees | (787) | (939) |
| Net long-term debt | $97,313 | $77,486 |

As of June 30, 2017, AMVAC Chemical Corporation (“AMVAC”), the Company’s principal operating subsidiary, as borrower, and affiliates (including the Company, AMVAC CV and AMVAC BV), as guarantors and/or borrowers, entered into a Third Amendment to Second Amended and Restated Credit Agreement (the “Credit Agreement”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and Letter of Credit (“L/C”) issuer. The Credit Agreement is a senior secured lending facility, consisting of a line of credit of up to $250,000, an accordion feature of up to $100,000 and a maturity date of June 30, 2022. The Credit Agreement contains two key financial covenants; namely, borrowers are required to maintain a Consolidated Funded Debt Ratio of no more than 3.25-to-1 and a Consolidated Fixed Charge Covenant Ratio of at least 1.25-to-1. The Company’s borrowing capacity varies with its financial performance, measured in terms of EBITDA, for the trailing twelve month period. Under the Credit Agreement, revolving loans bear interest at a variable rate based, at borrower’s election with proper notice, on either (i) LIBOR plus the “Applicable Rate” which is based upon the Consolidated Funded Debt Ratio (“Eurocurrency Rate Loan”) or (ii) the greater of (x) the Prime Rate, (y) the Federal Funds Rate plus 0.5%, and (z) the Daily One-Month LIBOR Rate plus 1.00%, plus, in the case of (x), (y) or (z) the Applicable Rate (“Alternate Base Rate Loan”). Interest payments for Eurocurrency Rate Loans are payable on the last day of each interest period (either one, two, three or six months, as selected by the borrower) and the maturity date, while interest payments for Alternate Base Rate Loans are payable on the last business day of each month and the maturity date.

At September 30, 2018, according to the terms of the Credit Agreement and based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $105,111. This compares to an available borrowing capacity of $124,724 as of September 30, 2017. The level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA for trailing twelve month period, which has improved, (2) net borrowings, which have increased and (3) the leverage covenant (being the number of times EBITDA the Company may borrow under its credit facility agreement).

We believe that anticipated cash flow from operations, existing cash balances and available borrowings under our senior credit facility will be sufficient to provide us with liquidity necessary to fund our working capital and cash requirements for the next twelve months.

### RECENTLY ISSUED ACCOUNTING GUIDANCE

Please refer to Note 14 in the accompanying Notes to the Condensed Consolidated Financial Statements for recently issued accounting standards.

### CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The Company continually re-assesses the critical accounting policies used in preparing its financial statements. In the Company’s Form 10-K filed with the SEC for the year ended December 31, 2017, the Company provided a comprehensive statement of critical accounting policies. These policies have been reviewed in detail as part of the preparation work for this Form 10-Q. After our review of these matters, we have determined that, during the subject reporting period, there has been no material change to the critical accounting policies that are listed in the Company’s Form 10-K for the year ended December 31, 2017. However, as of January 1, 2018 we adopted the new revenue recognition standard and the new income tax standard.

## Market risk

As filed, 1,323 characters.

The Company is exposed to market risk related to changes in interest rates, primarily from its borrowing activities. The Company’s indebtedness to its primary lender is evidenced by a line of credit with a variable rate of interest, which fluctuates with changes in the lender’s reference rate. For more information, please refer to the applicable disclosures in the Company’s Form 10-K filed with the SEC for the year ended December 31, 2017 and the Company’s Form 8-K filed with the SEC on or about July 6, 2017.

The Company conducts business in various foreign currencies, primarily in Europe, Mexico, Central and South America. Therefore changes in the value of the currencies of such countries or regions affect the Company’s financial position and cash flows when translated into U.S. Dollars. The Company has mitigated and will continue to mitigate a portion of its currency exchange exposure through natural hedges based on the operation of decentralized foreign operating companies in which the majority of all costs are local-currency based. Furthermore, the Company has established a procedure for covering forward exchange rates on specific purchase orders when appropriate. A 10% change in the value of all foreign currencies would have an immaterial effect on the Company’s financial position and cash flows.

## Controls and procedures

As filed, 1,090 characters.

As of September 30, 2018, the Company has a comprehensive set of disclosure controls and procedures designed to ensure that all information required to be disclosed in our filings under the Securities Exchange Act (1934) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As of September 30, 2018, the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, has concluded, based on their evaluation, that the Company’s disclosure controls and procedures are effective to provide reasonable assurance of the achievement of the objectives described above.

There were no changes in the Company’s internal controls over financial reporting that occurred during the most recent quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

### PART II. OTHER INFORMATION

(Dollars in thousands)

The Company was not required to report any matters or changes for any items of Part II except as disclosed below.

## Risk factors

As filed, 1,212 characters.

The Company continually re-assesses the business risks, and as part of that process detailed a range of risk factors in the disclosures in American Vanguard’s Report on Form 10-K for the fiscal year ended December 31, 2017, filed on March 14, 2018. In preparing this document, we have reviewed all the risk factors included in that document and find that there are no material changes to those risk factors.

**Tariff Activity –** Within recent months, the U.S. and China have imposed a series of retaliatory tariffs against one another in respect of various products, ranging from metals to grains to chemicals. To date, the Company has not been materially, adversely affected by these tariffs. However, it is not possible to predict which products could be targeted by either nation, nor is it possible to predict the size or duration of any given tariff. It is possible that either the U.S. or China could place tariffs on one or more products that would cause either a disruption in the markets of the Company’s customers or an increase in the Company’s cost of goods which, either individually or in the aggregate, could have a material adverse effect upon the Company’s operations or financial performance.

Filed Nov 6, 2018.
Source: SEC EDGAR, the filing index for accession 0001564590-18-027505. Last ingested by Listed: Nov 11, 2026, 00:16 ET. No prices; not investment advice.
